Home > Boards > US OTC > Medical - Drugs >


Add AVXT Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 2/5/2018 1:02:24 PM - Followers: 32 - Board type: Free - Posts Today: 0


Industry Center - Biotechnology

Contact Information
Address: 2000 Hamilton St., Ste. 204
Philadelphia, PA 19130
Phone: 215-241-9760
Fax: 215-241-9684
Key People
CEO: Adele Sommerfeld
BOD: Andrew W. Dahl Sc.D.; Serge Morrell
AVAX Technologies wants to turn cancer cells into cancer fighters. The company is developing vaccines created by extracting a patient's own cancer cells and chemically treating them to induce an immune system response. The technology used to create the vaccines (called AC Vaccine) is licensed from Thomas Jefferson University. AVAX's lead vaccine candidate MVax is intended as a treatment for late-stage melanoma. The company is also developing vaccine candidates to fight ailments such as ovarian cancer (OVax) and non-small cell lung cancer (LungVax).
Business Summary  

AVAX Technologies, Inc., a development stage biotechnology company, together with its subsidiaries, engages in the development and future commercialization of individualized vaccine therapies and other technologies for the treatment of cancer in the United States and Europe. The company's autologous cell vaccine candidates include M-Vax under Phase III clinical status, which is used for the treatment of melanoma; L-Vax under Phase I-II clinical status that is used for the treatment of non-small cell lung cancer; and O-Vax under Phase I-II clinical status, which is used for the treatment of ovarian cancer. It also offers biological manufacturing services to other biotechnology and pharmaceutical companies; and contract manufacturing services in for cell and gene therapy, and biological products in France. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.


AVAX Technologies, Inc. Files Form 10 With SEC

Press Release Source: AVAX Technologies, Inc. On Friday February 4, 2011, 12:41 pm EST

PHILADELPHIA, Feb. 4, 2011 /PRNewswire/ -- AVAX Technologies, Inc. (Pink - News) ("AVAX" or the "Company") today announced that it filed a Form 10 with the Securities and Exchange Commission ("SEC").  Upon the effectiveness of this Form 10, AVAX will once again become a publicly reporting company.  The Company intends to seek to have its common stock trade on the Over-the-Counter Bulletin Board.

The Company's Form 10, which contains among other things, recent information about the Company's business, operations, financial results and capitalization, can be accessed through the website maintained by the SEC at

About AVAX Technologies, Inc.

AVAX Technologies, Inc. is a biotechnology company headquartered in Philadelphia, PA.   The Company is engaged in the research and clinical and commercial development of biological products and cancer therapeutics.

The Company's AC Vaccine platform is a therapeutic cancer vaccine.

Forward-Looking Statements

Certain statements in this release are "forward-looking" statements.   Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by the Company that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. These statements include, but are not limited to, the Company's immediate need to obtain additional funding to continue to finance the Company, the Company's plans, objectives, projections, expectations and intentions such as those relating to the future development of M-VAX® and its other vaccine candidates, as well as other important factors discussed in the Company's Form 10.   The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events. 


Press Releases & AVAX Information:

2/4/2001: AVAX Technologies, Inc. Files Form 10 With SEC

AVAX Announces Settlement Agreement with Cancer Treatment Centers of America and Approves $45 Million Private Placement Financing


Published: Aug 4, 2015 7:31 p.m. ET


PHILADELPHIA, Aug 04, 2015 (BUSINESS WIRE) -- AVAX Technologies, Inc., (“AVAX” or “The Company”) (AVXT – OTCMKTS), a leading developer of proprietary cancer immunotherapy products, has signed a Settlement & Release Agreement with Cancer Treatment Centers of America Inc. (“CTCA”) to positively resolve the existing debt obligations owed to CTCA.

Under the terms of the Settlement Agreement, CTCA has agreed to settle its $5,826,464.73 Judgment against AVAX in exchange for 860,000 Series A Convertible Preferred Shares at a consideration of $5.00 per share, and a one-time payment of $1.5 million in cash. Firebird Management, a shareholder and a creditor of AVAX, has agreed to swap its outstanding debt for the Series A Convertible Preferred Shares also at a consideration of $5.00 per share.

Andrew Dahl, AVAX Board Member noted, “we are extremely happy to be able to move forward with the reorganization of AVAX’s balance sheet and look forward to re-commencing the important planned clinical trials at AVAX. Our previous work with CTCA on clinical programs has been very successful.”

Richard Rainey, Acting Chief Executive Officer of AVAX, stated, “We are pleased that throughout the development of our AC Vaccine® platform, all of our data has remained consistently positive and has supported further development of the treatment. We feel our immunotherapy platform is consistent with recently approved products and could be additive to the benefits achieved in helping patients with cancer.”

SGC Canada Inc., is acting on behalf of AVAX with its creditors in negotiating its informal restructuring plan. David Holden, the Senior Corporate Advisor of SGC states that “AVAX will be effectively debt-free once the Financial Restructuring & Refinancing Plan is completed.” The Board of AVAX has previously approved the engagement of Phoenix Corporate Finance Inc., a corporate finance firm which specializes in alternative financing, to advise, structure, and facilitate the distribution of a proposed Private Placement financing. through select securities dealers in the US and Canada. AVAX intends to raise $45 million to fund its next round of clinical testing through the issuance of the Series A Convertible Preferred Shares.




Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#240   Files Form 10 w/ SEC..... CHA$E 02/04/11 12:55:19 PM
#239   Yes, this definitely has never been an I-hub lefty18 01/30/11 10:06:37 AM
#238   Wow --- Dead board. ZZZZZZZZZZZZZzzzzzzzzzzzzz johnny canuck 01/29/11 10:43:55 PM
#237   I called a while back and the trial lefty18 01/20/11 05:37:28 PM
#236   Is AVXT your next ten bagger stock? rikic 01/14/11 07:09:22 AM
#235   Website is being updated. Please check back soon. rikic 01/13/11 09:04:18 AM
#234   Looks more like the Estimated end to the johnny canuck 01/11/11 08:22:22 PM
#233   Here it is, trial is done (primary) Superfly15 01/11/11 01:07:16 PM
#232   Something was updated on January 7th, trying to Superfly15 01/11/11 01:04:51 PM
#231   yes & many more to come :) startingboy 01/11/11 10:09:07 AM
#230   Looks like the start of a good day. :-) Zilla 01/11/11 09:46:24 AM
#229   Thanks Much, have a good one! ;O) VIPR 01/06/11 02:41:10 PM
#228   Someone else would be better but I think Zilla 01/06/11 02:39:34 PM
#227   when are the results do out? I haven't VIPR 01/06/11 02:35:41 PM
#226   Picked up 2K @ .07 because volume looking Zilla 01/06/11 02:28:44 PM
#225   when are the results do out? I haven't VIPR 01/06/11 01:48:20 PM
#224   insiders know first i think this volume are startingboy 01/06/11 10:10:00 AM
#223 Still nothing Superfly15 01/06/11 10:07:53 AM
#222   time is running out to get startingboy 01/06/11 10:01:03 AM
#221   I agree and that's why I at least Zilla 01/06/11 09:57:12 AM
#220   but this time could be spectacular if the startingboy 01/06/11 09:55:06 AM
#219   This happened with the last run up. Someone Zilla 01/06/11 09:52:33 AM
#218   .06x.065 ut without volume hmmmm :) startingboy 01/06/11 09:48:46 AM
#217   Picked up a taste of 10K @ .056 Zilla 01/05/11 12:23:48 PM
#216   Had to do first aid/CPR/AED training today so Zilla 01/04/11 07:04:14 PM
#215   83k block at .06 nice startingboy 01/04/11 11:18:59 AM
#214   Zilla stop buying all the shares !! :-D Superfly15 01/04/11 11:16:56 AM
#213   Thats a nice chuck of volume for AVXT...Nice Zilla 01/04/11 11:13:55 AM
#212   someone just grabbed a bunch hmmmm good OVax® startingboy 01/04/11 10:58:28 AM
#211   Haha, yeah man I watched ADLS down there Superfly15 01/03/11 10:47:25 PM
#210   I want some under .03 but they don't Zilla 01/03/11 10:01:51 PM
#209   Watch this for an update to the trial Superfly15 01/03/11 09:43:35 PM
#208   Hi Lefty, I just wanted to find this Zilla 12/21/10 08:08:48 PM
#207   That was moving. Thanks for sharing that. lefty18 11/15/10 12:04:36 PM
#206   inspiring story startingboy 11/12/10 08:55:48 AM
#205   check this video startingboy 11/12/10 08:44:57 AM
#204   I'm confident from the results that I've read lefty18 10/25/10 02:55:31 PM
#203   i got $ ready waiting for any dip startingboy 10/25/10 10:29:46 AM
#202   Cha-Ching. Dr. Coukos anticipates that in the future, immunotherapy lefty18 10/22/10 10:45:27 PM
#201 startingboy 10/22/10 02:08:09 PM
#200   and results are just around the corner startingboy 10/19/10 09:58:37 AM
#199   No I hadn't seen that, nice find. :-) Zilla 10/19/10 09:56:58 AM
#198   check the CTCA Outcomes Data on survival on startingboy 10/19/10 09:55:27 AM
#197   zilla you see this? startingboy 10/19/10 09:46:34 AM
#196   Thanks, "lefty", let's hope there will be no medimpact 10/12/10 05:40:52 PM
#195   Estimated primary completion date: Jan '11 lefty18 10/12/10 03:01:28 PM
#194   Ya can't do salvage chemotherapy regimens on dead lefty18 10/12/10 01:19:03 PM
#193   I should restate that part about something concrete lefty18 10/06/10 02:04:27 PM
#192   Down 20% on 339,000 shares. Zilla 10/05/10 04:04:13 PM
#191   Nice low volume to make people forget. :-) Zilla 10/05/10 11:54:44 AM